Zacks Research Has Optimistic Outlook of Zoetis Q3 Earnings

Zoetis Inc. (NYSE:ZTS - Free Report) - Investment analysts at Zacks Research upped their Q3 2025 earnings per share (EPS) estimates for shares of Zoetis in a note issued to investors on Monday, May 26th. Zacks Research analyst E. Bagri now expects that the company will earn $1.67 per share for the quarter, up from their prior estimate of $1.62. The consensus estimate for Zoetis' current full-year earnings is $6.07 per share. Zacks Research also issued estimates for Zoetis' Q4 2025 earnings at $1.54 EPS, FY2025 earnings at $6.28 EPS, Q1 2026 earnings at $1.58 EPS, Q2 2026 earnings at $1.70 EPS, Q3 2026 earnings at $1.73 EPS, Q4 2026 earnings at $1.75 EPS and FY2026 earnings at $6.76 EPS.

A number of other research analysts have also recently commented on ZTS. Barclays raised their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research note on Friday, February 14th. UBS Group decreased their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Piper Sandler lifted their price objective on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Monday, May 12th. Morgan Stanley cut their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Finally, Wall Street Zen raised shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Zoetis has a consensus rating of "Buy" and an average target price of $212.75.

Zoetis Stock Performance

ZTS stock traded down $0.47 during midday trading on Thursday, hitting $168.17. The stock had a trading volume of 1,106,024 shares, compared to its average volume of 2,521,471. The stock has a 50-day simple moving average of $156.80 and a 200 day simple moving average of $164.43. The firm has a market capitalization of $74.87 billion, a price-to-earnings ratio of 30.76, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis has a 52 week low of $139.70 and a 52 week high of $200.33. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Zoetis's revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.38 earnings per share.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be issued a $0.50 dividend. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.19%. Zoetis's dividend payout ratio (DPR) is presently 35.91%.

Insiders Place Their Bets

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares in the company, valued at approximately $2,682,770. This represents a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.18% of the company's stock.

Institutional Trading of Zoetis

Hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its holdings in Zoetis by 10.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company's stock valued at $569,834,000 after acquiring an additional 279,092 shares in the last quarter. Brighton Jones LLC raised its stake in shares of Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock valued at $754,000 after acquiring an additional 2,978 shares during the last quarter. PFG Investments LLC grew its position in shares of Zoetis by 3.7% in the 4th quarter. PFG Investments LLC now owns 3,265 shares of the company's stock valued at $532,000 after buying an additional 115 shares during the last quarter. Blue Trust Inc. lifted its position in shares of Zoetis by 85.1% in the 4th quarter. Blue Trust Inc. now owns 9,353 shares of the company's stock worth $1,524,000 after purchasing an additional 4,301 shares during the period. Finally, Pacer Advisors Inc. boosted its stake in shares of Zoetis by 12.4% in the 4th quarter. Pacer Advisors Inc. now owns 52,401 shares of the company's stock valued at $8,538,000 after purchasing an additional 5,790 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.